Seelos Therapeutics Stock Alpha and Beta Analysis
| SEEL Stock | USD 0.39 0.11 22.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Seelos Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Seelos Therapeutics over a specified time horizon. Remember, high Seelos Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Seelos Therapeutics' market risk premium analysis include:
Beta (4.28) | Alpha (3.06) | Risk 15.08 | Sharpe Ratio (0.23) | Expected Return (3.40) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Seelos |
Seelos Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Seelos Therapeutics market risk premium is the additional return an investor will receive from holding Seelos Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Seelos Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Seelos Therapeutics' performance over market.| α | -3.06 | β | -4.28 |
Seelos Therapeutics Fundamentals Vs Peers
Comparing Seelos Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Seelos Therapeutics' direct or indirect competition across all of the common fundamentals between Seelos Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Seelos Therapeutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Seelos Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Seelos Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Seelos Therapeutics to competition |
| Fundamentals | Seelos Therapeutics | Peer Average |
| Return On Equity | -5.84 | -0.31 |
| Return On Asset | -2.61 | -0.14 |
| Profit Margin | 2.03 % | (1.27) % |
| Operating Margin | (8.35) % | (5.51) % |
| Current Valuation | 10.45 M | 16.62 B |
| Shares Outstanding | 581 K | 571.82 M |
| Shares Owned By Insiders | 0.49 % | 10.09 % |
Seelos Therapeutics Opportunities
Seelos Therapeutics Return and Market Media
The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
About Seelos Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Seelos or other otcs. Alpha measures the amount that position in Seelos Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Seelos Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Seelos Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Seelos Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Seelos Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Seelos Therapeutics. Please utilize our Beneish M Score to check the likelihood of Seelos Therapeutics' management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Seelos Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Other Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.